Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma

被引:53
作者
Koyama, S [1 ]
Koike, N
Adachi, S
机构
[1] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Inst Clin Med, Dept Surg, Tsukuba, Ibaraki 305, Japan
关键词
Fas receptor; Fas ligand; immune privilege; apoptosis; gastric carcinoma;
D O I
10.1007/s004320000181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the presence and functional status of surface expression of the Fas receptor (FasR) and its ligand (FasL) in tumor and tumor-infiltrating lymphocytes (TIL) in gastric carcinoma (n = 36) from the primary locus, metastatic gastric carcinoma (n = 30) from malignant ascites, and benign gastric mucosa (n = 30) for the control. The quantitative analysis was based on the percentage of positive cells by a flow cytometry. The results showed that the membrane-bound FasL molecule was constitutively expressed in primary and metastatic gastric carcinomas as well as normal gastric epithelium in nearly all the patients. III particular, metastatic carcinoma proved to aberrantly express the FasL molecule. On the other hand, FasR expression ranged from minimal or absent in primary and metastatic gastric carcinomas: suggesting that the carcinoma might be rendered less sensitive toward FasL-induced killing. Apoptotic tumor cells detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTTP nick and labeling (TUNEL) were barely identified in primary and metastatic carcinomas. In the analysis of TIL, the expression of FasR and Fast, and apoptotic TIL could not usually be observed in primary gastric carcinoma. In metastatic carcinoma, however, there was significant overexpression of FasR and FasL in immune TIL associated with a higher frequency of apoptotic cell death detected by TUNEL. The results suggest that metastatic carcinoma expressing FasL, but not FasL(+) primary carcinoma, might evade the immune attack by apoptotic depletion of activated TIL through the FasR:FasL systems. These results provide the direct and quantitative evidence of FasR counterattacks and/or paracrine fratricides as a mechanism of tumor-immune escape in vivo in human cancer.
引用
收藏
页码:20 / 26
页数:7
相关论文
共 34 条
[1]   Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts [J].
Allison, J ;
Georgiou, HM ;
Strasser, A ;
Vaux, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3943-3947
[2]  
[Anonymous], GASTRIC CANC
[3]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[4]   Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer [J].
Bennett, MW ;
O'Connell, J ;
O'Sullivan, GC ;
Roche, D ;
Brady, C ;
Kelly, J ;
Collins, JK ;
Shanahan, F .
GUT, 1999, 44 (02) :156-162
[5]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717
[6]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[7]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[8]  
Hoshino T, 1997, INT J CANCER, V70, P631, DOI 10.1002/(SICI)1097-0215(19970317)70:6<631::AID-IJC1>3.3.CO
[9]  
2-I
[10]   FAS AND PERFORIN PATHWAYS AS MAJOR MECHANISMS OF T-CELL-MEDIATED CYTOTOXICITY [J].
KAGI, D ;
VIGNAUX, F ;
LEDERMANN, B ;
BURKI, K ;
DEPRAETERE, V ;
NAGATA, S ;
HENGARTNER, H ;
GOLSTEIN, P .
SCIENCE, 1994, 265 (5171) :528-530